Tidal Investments LLC raised its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 8.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 142,486 shares of the company's stock after buying an additional 11,358 shares during the period. Tidal Investments LLC's holdings in Kenvue were worth $3,042,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of KVUE. Geneos Wealth Management Inc. bought a new position in Kenvue during the fourth quarter worth about $29,000. SRS Capital Advisors Inc. increased its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Asset Planning Inc acquired a new position in Kenvue during the fourth quarter worth approximately $42,000. Clarity Asset Management Inc. acquired a new position in Kenvue during the fourth quarter worth approximately $45,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Kenvue during the fourth quarter worth approximately $46,000. 97.64% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
KVUE has been the subject of a number of research analyst reports. Canaccord Genuity Group boosted their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Piper Sandler upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Redburn Atlantic started coverage on Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Evercore ISI initiated coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Finally, Barclays increased their price objective on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Kenvue has a consensus rating of "Hold" and an average target price of $25.33.
View Our Latest Report on Kenvue
Kenvue Stock Up 1.1%
NYSE:KVUE traded up $0.26 on Friday, hitting $23.76. The stock had a trading volume of 10,164,041 shares, compared to its average volume of 16,369,512. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market cap of $45.59 billion, a P/E ratio of 44.83, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $25.17. The firm's fifty day simple moving average is $23.23 and its two-hundred day simple moving average is $22.62.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company's revenue for the quarter was down 3.9% on a year-over-year basis. During the same quarter last year, the business posted $0.28 EPS. Analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.45%. Kenvue's payout ratio is currently 149.09%.
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
